Effects of steroid hormones on the secretion of hemostatic factors in, and angiogenic properties of, human vascular endothelial cells

References

• Colditz G. A., Willett W. C., Stampfer M. J., Rosner B., Speizer F. E., Hennekens C. H. Menopause and the risk of coronary heart disease in women. N. Engl. J. Med. 1987; 316: 1105–10
   PubMed Web of Science ®Google Scholar
• Bush T. L., Barrett-Connor E., Cowan L. D., Criqui M. H., Wallace R. B., Suchindran C. M., Tyroler H. A., Rifkind B. M. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–9
   PubMed Web of Science ®Google Scholar
• Sullivan J. M., Van der Zwaag R., Lemp G. F., Hughes J. P., Maddock V., Kroetz F. W., Ramanathan K. B., Mirvis D. M. Postmenopausal estrogen use and coronary atherosclerosis. Ann. Intern. Med. 1988; 108: 358–63
   PubMed Web of Science ®Google Scholar
• Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med. 1991; 325: 756–62
   PubMed Web of Science ®Google Scholar
• Kuhn F. E., Rackley C. E. Coronary artery disease in women: risk factors, evaluation, treatment, and prevention. Arch. Intern. Med. 1993; 143: 2626–36
   Google Scholar
• Knopp R. H. The effects of postmenopausal estrogen therapy on the incidence of arterioselerotic vascular disease. Obstet. Gynecol. 1988; 72: 23S–30S
   PubMed Web of Science ®Google Scholar
• Writing group for PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J. Am. Med. Assoc. 1995; 273: 199–208
   Google Scholar
• Barrett-Connor E., Bush T. L. Estrogen and coronary heart disease in women. J. Am. Med. Assoc. 1991; 265: 1861–7
   PubMed Web of Science ®Google Scholar
• Collins P., Rosano G. M. C., Jiang C., Lindsay D., Sarrel P. M., Poole-Wilson P. A. Hypothesis: cardiovascular protection by oestrogen: a calcium antagonist effect. Lancet 1993; 341: 1264–5
   PubMed Web of Science ®Google Scholar
• Hayashi T., Fukuto J. M., Ignarro L. J., Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc. Natl. Acad. Sci. USA 1992; 89: 11259–63
   PubMed Web of Science ®Google Scholar
• Van Buren G., Yang D., Clark K. E. Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am. J. Obstet. Gynecol. 1992; 16: 828–33
   Google Scholar
• Polderman K. H., Stehouwer C. D. A., Van Kamp G. J., Dekker G. A., Verheugt F. W. A., Gooren L. J.G. Influence of sex hormones on plasma endothelin levels. Ann. Intern. Med. 1993; 118: 429–32
   PubMed Web of Science ®Google Scholar
• Mikkola T., Turunen P., Avela K., Orpana A., Viinikka L., Ylikorkala O. 17β-estradlol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J. Clin. Endocrinol. Metab. 1995; 80: 1832–6
   PubMed Web of Science ®Google Scholar
• Van den Eijnden-Schrauwen Y., Kooistra T., De Vries R. E. M., Emeis J. J. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood 1995; 85: 3510–17
   Google Scholar
• Sinha S., Wagner D. D. Intact microtubules are necessary for complete processing, storage and regulated secretion of von Willebrand factor by endothelial cells. Cell Biol. 1987; 43: 377–83
   Google Scholar
• D'Amato R. J., Lin C. M., Flynn E., Folkman J., Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA 1994; 91: 3964–8
   PubMed Web of Science ®Google Scholar
• Fotsis T., Zhang Y., Pepper M. S., Adlercreutz H., Montesano R., Nawroth P. P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237–9
   PubMed Web of Science ®Google Scholar
• Morales D. E., McGowan K. A., Grant D. S., Maheshwari S., Bhartiya D., Cid M. C., Kleinman H. K., Schnaper H. W. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in murine model. Circulation 1995; 91: 755–63
   PubMed Web of Science ®Google Scholar
• Koolwijk P., Van Erck M. G.M., De Vree W. J. A., Vermeer M. A., Weich H. A., Hanemaaijer R., Van Hinsbergh V. W.M. Cooperative effect of tumor necrosis factor a and angiogenic growth factors on the formation of tubular structures of human microvascular endothelial cells in a three-dimensional fibrin matrix. Role of pericellular urokinase activity. J. Cell. Bid 1996; 132: 1177–88
   PubMed Web of Science ®Google Scholar
• Siegbahn A., Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb. Haemostas. 1988; 60: 361–4
   PubMed Web of Science ®Google Scholar
• Gevers Leuven J. A., Kluft C., Bertina R. M., Hessel L. W. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J. Lab. Clin. Med. 1987; 109: 631–6
   Google Scholar
• Anderson R. A., Ludlam C. A., Wu F. C.W. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb. Haemostas. 1995; 74: 693–7
   PubMed Web of Science ®Google Scholar
• Caron P., Bennet A., Camare R., Louvet J. P., Boneu B., Sié P. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989; 38: 1010–5
   PubMed Web of Science ®Google Scholar
• Kooistra T., Bosma P. J., Jespersen J., Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am. J. Obstet. Gynecol. 1990; 163: 404–12
   PubMed Web of Science ®Google Scholar
• Cho H., Katzenellenbogen B. S. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Mol. Endocrinol. 1993; 7: 441–52
   PubMedGoogle Scholar
• Kounnas M. Z., Henkin J., Argraves W. S., Strickland D. K. Low density lipoprotein receptor-related protein/α2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J. Biol. Chem. 1993; 268: 21862–7
   PubMedGoogle Scholar
• Narita M., Bu G., Hen J., Schwartz A. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J. Clin. Invest. 1995; 96: 1164–8
   PubMed Web of Science ®Google Scholar
• Harrison R. L., McKee P. A. Estrogen stimulates von Willebrand Factor production by cultured endothelial cells. Blood 1984; 63: 657–65
   PubMed Web of Science ®Google Scholar
• Kooistra T., Van den Berg J., Töns A., Platenburg G., Rijken D. C., Van den Berg E. Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells. Biochem. J. 1987; 247: 605–12
   PubMedGoogle Scholar
• Chester A. H., Jiang C., Borland J. A., Yacoub M. H., Collins P. Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron. Art. Dis. 1995; 6: 417–22
   PubMed Web of Science ®Google Scholar
• Pepper M. S., Vassalli J.-D., Wilks J. W., Schweigerer L., Orci L., Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell. Biochem. 1994; 55: 419–34
   PubMed Web of Science ®Google Scholar
• Battegay E. J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 1995; 73: 333–46
   PubMed Web of Science ®Google Scholar